rs17249754 — ATP2B1

ATP2B1 rs17249754 — A Second Calcium Pump Variant Tuning Blood Pressure

Running just 80 kilobases downstream of the widely-studied rs2681472 variant at the same gene, rs17249754 is an independent intronic variant in ATP2B1¹¹ ATP2B1
encodes Plasma Membrane Ca²⁺-ATPase 1 (PMCA1), the primary pump ejecting calcium from inside cells to the extracellular space — essential for maintaining low intracellular calcium in vascular smooth muscle. Like its neighboring variant, rs17249754 has reached genome-wide significance in multiple large international consortia, but its risk story has an unusual twist: the common G allele (~83% in Europeans, ~65% in East Asians) is the blood pressure-raising allele, while the rarer A allele is protective. Most people carry at least one G allele without knowing it.

The Mechanism

rs17249754 sits within an intron of ATP2B1 on chromosome 12q21.33, position 89,666,809 (GRCh38)²² chromosome 12q21.33, position 89,666,809 (GRCh38). The intronic location means it does not alter the protein sequence of PMCA1 directly; instead, it acts as a regulatory variant affecting gene expression levels in vascular tissue. The G allele is associated with reduced ATP2B1 expression in arterial and aortic endothelial cells — fewer functional PMCA1 pumps per cell.

PMCA1 is the dominant calcium extrusion mechanism in vascular smooth muscle cells. When pump density falls, intracellular calcium rises, driving sustained smooth muscle contraction and vasoconstriction. Separately, PMCA1 physically associates with eNOS³³ eNOS
endothelial nitric oxide synthase, which produces the vasodilator nitric oxide: impaired PMCA1 activity reduces eNOS output, removing a key vasodilatory signal. Both effects — higher calcium and lower nitric oxide — converge on elevated vascular resistance and raised blood pressure.

Mouse models directly validate this pathway: heterozygous PMCA1-null animals develop elevated blood pressure, and vascular smooth muscle-specific knockout mice show increased intracellular calcium with hypertension. Strikingly, aging heterozygous PMCA1-null mice exhibit arterial wall thickening and lumen narrowing before blood pressure rises⁴⁴ aging heterozygous PMCA1-null mice exhibit arterial wall thickening and lumen narrowing before blood pressure rises, suggesting subclinical vascular remodelling may precede measurable hypertension by years.

The Evidence

The ICBP consortium analysis⁵⁵ ICBP consortium analysis
International Consortium for Blood Pressure Genome-Wide Association Studies in approximately 200,000 European-ancestry participants placed rs17249754 among 29 genome-wide significant blood pressure loci: each G allele raises systolic BP by 0.928 mmHg (p=1.8×10⁻¹⁸) and diastolic BP by 0.522 mmHg (p=1.2×10⁻¹⁴). These effect sizes are per-allele, meaning GG homozygotes carry approximately 1.86 mmHg higher systolic and 1.04 mmHg higher diastolic BP than the rare AA genotype.

The original Korean discovery⁶⁶ original Korean discovery in 16,703 Korean participants (KARE and Health2 cohorts) found rs17249754 was the strongest ATP2B1 signal for hypertension (p=4.25×10⁻⁹) — stronger than the neighboring rs2681472, which predominates in European analyses. A 2021 meta-analysis of 65,362 individuals across 9 studies⁷⁷ 2021 meta-analysis of 65,362 individuals across 9 studies confirmed the association globally: hypertension OR=1.19 (95%CI 1.10–1.28) per G allele. Cross-ethnic replication in 55,383 East Asian participants (stage 1+2)⁸⁸ in 55,383 East Asian participants (stage 1+2) confirmed the locus for mean arterial pressure (p=7.5×10⁻¹⁵) and pulse pressure (p=1.2×10⁻⁵). Replication extends to African (Burkina Faso), Chinese children, and South Asian populations.

A critical dietary interaction has been documented. In a Korean cohort of 14,354 participants⁹⁹ Korean cohort of 14,354 participants, G allele (major allele) carriers showed substantially higher systolic BP risk when calcium intake was low and the dietary sodium-to-potassium ratio was high. Conversely, A allele carriers (the protective minority) gained the greatest benefit from high potassium intake and a low sodium-to-potassium ratio. This gene-diet interaction is directly actionable: PMCA1 insufficiency from the G allele is exacerbated when dietary calcium is unavailable to compensate for impaired efflux.

Practical Actions

For GG carriers, three strategies target the underlying mechanism most directly. Maintaining dietary calcium at 1,000–1,200 mg/day is the most genotype-specific intervention: low calcium amplifies the blood pressure risk from reduced PMCA1 activity at a cellular level. Reducing the dietary sodium-to-potassium ratio — through sodium reduction and potassium-rich foods — addresses the salt-sensitivity component documented in this variant's cohort studies. Regular home blood pressure monitoring enables early detection of the gradual pressure elevation this variant drives. For AG heterozygotes, the same dietary targets apply with attenuated urgency — the additive effect model means they carry approximately half the genotype-attributable BP elevation.

Interactions

rs17249754 and rs2681472 are both intronic ATP2B1 variants in partial linkage disequilibrium. rs2681472 is the stronger signal in European-ancestry GWAS; rs17249754 is stronger in East Asian cohorts. Carriers of risk alleles at both variants may have compounded calcium-mediated BP elevation, though formal compound action studies documenting the interaction effect are not yet published.

Within the blood pressure regulatory network, ATP2B1 interacts functionally with AGT (rs699, angiotensinogen M235T) and NOS3 (rs1799983, eNOS Glu298Asp). Angiotensin II elevates intracellular calcium in vascular smooth muscle — a signal that depends on PMCA1 for clearance. Reduced PMCA1 in G allele carriers means angiotensin II-driven calcium signals persist longer. Similarly, impaired PMCA1 reduces the calcium/calmodulin signal available to activate eNOS, compounding the effect of any eNOS Glu298Asp-associated nitric oxide deficit.